Prothena (PRTA) Scheduled to Post Quarterly Earnings on Wednesday

Prothena (NASDAQ:PRTA) is set to post its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Prothena to post earnings of ($1.21) per share for the quarter.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.03). Prothena had a negative return on equity of 24.84% and a negative net margin of 160.91%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. Prothena’s revenue was down 99.4% compared to the same quarter last year. On average, analysts expect Prothena to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Prothena Stock Performance

NASDAQ PRTA traded down $0.14 during mid-day trading on Tuesday, hitting $23.60. The stock had a trading volume of 26,823 shares, compared to its average volume of 729,138. The company has a 50 day simple moving average of $24.56 and a 200 day simple moving average of $30.70. Prothena has a 52-week low of $19.65 and a 52-week high of $79.38.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PRTA shares. StockNews.com cut shares of Prothena from a “hold” rating to a “sell” rating in a research note on Monday, February 19th. JMP Securities upped their price objective on Prothena from $81.00 to $85.00 and gave the stock a “market outperform” rating in a report on Friday, February 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a report on Wednesday, April 10th. Bank of America reiterated a “neutral” rating and set a $38.00 price target (down previously from $68.00) on shares of Prothena in a report on Tuesday, January 30th. Finally, Royal Bank of Canada decreased their target price on shares of Prothena from $36.00 to $35.00 and set a “sector perform” rating on the stock in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Prothena presently has an average rating of “Moderate Buy” and an average price target of $68.14.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.